Treatment of Helicobacter pylori Infection

Helicobacter

Volumn 11, Issue SUPPL.1, 2006, Pages 36-39

  Cavallaro, Lucas G ^a   Egan, Brian ^b   O'Morain, Colm ^b   Di Mario, Francesco ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Antimicrobial resistance; Eradication; First line treatment

Indexed keywords

ANTIINFECTIVE AGENT; ANTIULCER AGENT; CLARITHROMYCIN; PROTON PUMP;

ADULT; ANTIBIOTIC RESISTANCE; CHILD; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MICROBIOLOGY; REVIEW; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CHILD; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROTON PUMPS; TREATMENT OUTCOME;

EID: 33947178200     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1478-405X.2006.00428.x     Document Type: Article

References (38)

1. Della Monica P, Lavagna A, Masoero G, Lombardo L. C Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-75.
2. Boixeda D, Martin De Argila C, Bermejo F, Lopez Sanroman A, Hernandez Ranz F, Garcia Plaza A. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. Factors that influence Helicobacter pylori eradications success. Rev Esp Enferm Dig 2003;95:202-5.
3. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26. Erratum in: Aliment Pharmacol Ther: 2003 May 1;17:1205.
4. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP; Hp Study Group of the Asociacion Espanola de Gastroenterologia. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005;100:1696-701.
5. Malfertheiner P, Megraud F, O'Morain C. The Maastricht 3 Consensus Report: Guidelines for the Management of Helicobacter pylori infection. Eur Gastroenterol Rev 2005;59:62 [http://www.helicobacter.org/download/summary_guidelines_hp_infection%20_business_briefing.pdf].
6. Malfertheiner P, Mégraud F, O'Morain C, Hungins APS, Jones R, Axon A, Graham DY, Tytgat G & The European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
7. Cardenas VM, Mulla ZD, Ortiz M, Graham D. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 2005;163:127-34.
8. Baggett HC, Parkinson AJ, Muth PT, Gold BD, Gessner B. Endemic iron deficiency associated with Helicobacter pylori infection among school-aged children in Alaska. Pediatrics 2006;117:396-404.
9. DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005;100:453-9.
10. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998;352:878.
11. Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori -positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005;81:162-8.
12. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005;21:1411-8.
13. Megraud F. Helicobacter pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;33:1374-84.
14. Antos D, Schneider-Brachert W, Bastlein E, et al. 7-Day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter 2006;11:39-46.
15. De Francesco V, Margiotta M, Zulllo A, et al. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. Aliment Pharmacol Ther 2006;23:429-35.
16. Koletzko S, Richy F, Bontems P, et al. on the behalf of the European Paediatric Task Force on Helicobacter pylori. Prospective multicenter study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006;April 7 (Epub ahead of print).
17. Cardenas VM, Graham DY, El-Zimaity HMT, Opekun AR, Campos A, Chavez A, Guerrero L. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther 2006;23:295-301.
18. Nishizawa T, Suzuki H, Kurabayashi K, Masaoka T, Muraoka H, Mori M, Iwasaki E, Kobayashi I, Hibi T. Gatifloxacin resistance and mutations in gyr A after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob Agents Chemother 2006;50:1538-40.
19. Lamouliatte H, Megraud F, Delchier JC, et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 2003;18:791-7.
20. Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG, Ferri A, Ciccaglione AF, Grossi L, Marzio L. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:1639-43.
21. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP on behalf of the Hp Study Group of the Asociación Espa 1 ola de Gastroenterologia. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori. Am J Gastroenterol 2005;100:1696-701.
22. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006;119:217-24.
23. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive. Cochrane Database Syst Rev 2003.
24. Dore MP, Maragkoudakis E, Pironti A, Tadeu V, Tedde R, Realdi G, Delitala G. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter 2006;11:52-5.
25. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapy therapies, and with 10-day sequential regimen. Can J Gastroenterol 2006;20:113-7.
26. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycinresistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100.
27. Okuda M, Nakazawa T, Yamauchi K, et al. Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo controlled study. J Infect Chemother 2005;11:265-9.
28. Di Mario F, Aragona G, Dal Bo N, et al. on the behalf of the Gastrointestinal Study Group (GISU). Bovine lactoferrin for the Helicobacter pylori eradication: an open, randomized, multicentre study. Aliment Pharmacol Ther 2006;23:1235-40.
29. Zullo A, De Francesco V, Scaccianoce G, Hassan C, Panarese A, Piglionica D, Panella C, Morini S, Ierardi E. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig Liver Dis 2005;37:496-500.
30. Matsushima M, Suzuki T, Kurumada T, et al. Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies Helicobacter pylori infection. J Gastroenterol Hepatol 2006;21:232-3.
31. Murakami K, Sato R, Okimoto T, Watanabe K, Nasu M, Fujioka T, Kodama M, Abe T, Sato S, Arita T. Effectiveness of minocyclinebased triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2006;21:262-7.
32. Sheu BS, Cheng HC, Kao AW, Wang ST, Yang YJ, Yang HB, Wu JJ. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradication residual Helicobacter pylori after failed triple therapy. Am J Clin Nutr 2006;83:864-9.
33. Cheon JU, Kim N, Lee DH, Kim JS, Jung HC, Song IS. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006;11:46-51.
34. Gisbert JP, De la morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Phar Ther 2006;23:35-44.
35. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
36. Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. A study of 4- and 7-day triple therapy with rabeprazole, high-dose levofloxacin and tinidazole rescue treatment for Helicobacter pylori eradication. Aliment Phar Ther 2005;23:281-7.
37. Borody TJ, Pang G, Wettstein AR, Clancy R, Herman K, Surace R, Fiorente R, Ng C. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Phar Ther 2006;23:481-8.
38. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-6.